Welcome to our dedicated page for Corbus Pharmaceuticals Holdings news (Ticker: $CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceuticals Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Corbus Pharmaceuticals Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Corbus Pharmaceuticals Holdings's position in the market.
Corbus Pharmaceuticals reported its first-quarter 2024 financial results, highlighting the dosing of the first patient in the U.S. Phase 1 clinical trial of CRB-701, targeting Nectin-4. The company raised $116 million in capital, extending its cash runway through Q1 2027, and appointed Dr. Dominic Smethurst as Chief Medical Officer. CRB-701 Phase 1 data will be presented at ASCO Annual Meeting on June 1, 2024.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) will participate in the BTIG Obesity Health Forum with CEO Yuval Cohen joining a panel discussion on CB1 Axis Therapies for Obesity on May 8, 2024. The event will be held virtually, offering insights into the company's innovative approaches to addressing obesity.
